外泌体在抑郁症中的机制、诊断潜力与治疗机会
本文综述外泌体在抑郁症中的作用,涵盖其携带miRNA、蛋白质等货物调节神经炎症、突触重塑、HPA轴和肠脑沟通的机制。人源和临床前证据提示循环及脑源性外泌体货物改变与MDD及TBI后继发性抑郁相关,但人类数据多为横断面关联。治疗上MSC来源外泌体在啮齿类模型显示抗抑郁样效应,工程化及iPSC来源外泌体具转化潜力,但分离标准化和来源归属等问题限制临床转化。
要点
- 外泌体通过miRNA、蛋白质等货物调节神经炎症、突触可塑性、HPA轴和肠脑沟通,参与抑郁症病理生理。
- 循环神经元富集外泌体携带miR-16、miR-124等被提议作为微创生物标志物,但人类证据多为横断面关联。
- MSC来源外泌体在啮齿类模型显示抗抑郁样效应,工程化及iPSC来源外泌体具治疗平台潜力。
核心结论
- 外泌体研究处于早期但快速发展的转化阶段,需方法学标准化和纵向验证以确定其精准精神病学价值。
研究设计与样本
- 本文为综述,汇总人源和临床前研究证据,未报告系统检索范围。
主要发现
- 循环和脑源性外泌体货物改变与MDD及TBI后继发性抑郁相关,涉及共享炎症和突触通路及不同病因驱动。
- 循环神经元富集外泌体携带miR-16和miR-124被提议作为反映脑相关分子改变的微创生物标志物。
- MSC来源外泌体在啮齿类模型通过调节小胶质细胞活化、增强突触可塑性和减弱神经炎症级联产生抗抑郁样效应。
- 工程化外泌体提供靶向递送抗炎或神经可塑性增强货物的潜在平台。
- iPSC来源外泌体代表潜在可扩展和标准化的治疗平台。
临床怎么用
- 外泌体作为抑郁症生物标志物尚需纵向验证和细胞来源确认,暂不宜临床常规使用。
- 外泌体治疗策略仍处于临床前阶段,需方法学标准化后方可推进临床转化。
局限性
- 多数人类数据为横断面和关联性,缺乏纵向重复验证。
- 外泌体分离流程(超速离心、尺寸排阻色谱、免疫亲和捕获)在产量、纯度和可重复性上存在差异,影响跨队列可比性。
- 外周生物流体中囊泡来源的确定性归属仍受技术限制。
- 标准化报告框架应用不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Exosomes are increasingly recognized as critical mediators of intercellular communication within the central nervous system and along the brain-periphery axis, with emerging relevance to the pathophysiology of depression. These nanoscale extracellular vesicles transport bioactive cargo-including microRNAs (miRNAs), proteins, lipids, and metabolites-that can modulate neuroinflammatory signaling, synaptic remodeling, hypothalamic-pituitary-adrenal (HPA) axis dynamics, and gut-brain communication. Converging evidence from human and preclinical studies suggests that alterations in circulating and brain-derived exosomal cargo are associated with major depressive disorder (MDD) and secondary depression following neurological insults such as traumatic brain injury (TBI), implicating shared inflammatory and synaptic pathways alongside distinct etiological drivers. Circulating neuron-enriched exosomes carrying miRNAs such as miR-16 and miR-124 have been proposed as minimally invasive biomarkers reflecting brain-relevant molecular alterations. However, most human data remain cross-sectional and associative, with limited longitudinal replication and incomplete validation of cellular origin. Therapeutically, mesenchymal stem cell (MSC)-derived exosomes demonstrate antidepressant-like effects in rodent models through modulation of microglial activation, enhancement of synaptic plasticity, and attenuation of neuroinflammatory cascades. Engineered exosomes further offer a potential platform for targeted delivery of anti-inflammatory or neuroplasticity-enhancing cargo. Induced pluripotent stem cell (iPSC)-derived exosomes represent a potentially scalable and standardizable therapeutic platform. Despite this promise, substantial barriers impede clinical translation. Isolation workflows-including ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture-vary in yield, purity, and reproducibility, complicating cross-cohort comparability. Moreover, definitive attribution of vesicle origin in peripheral biofluids remains technically constrained, and standardized reporting frameworks are inconsistently applied. Advances in multi-omics profiling, high-throughput sequencing, mass spectrometry, and spatially resolved molecular analyses may improve mechanistic resolution and biomarker robustness. Collectively, exosome research in depression resides at an early but rapidly evolving translational stage. Rigorous methodological standardization, longitudinal cohort validation, and mechanistic dissection across primary and injury-related depression will be essential to determine whether exosome-based diagnostics and therapeutics can fulfill their potential within precision psychiatry.
引用
- Wang F, Yang J, Wang G, et al. Exosomes in depression: mechanistic insights, diagnostic potential, and therapeutic opportunities. Mol Psychiatry. 2026. PMID: 42050011. doi:10.1038/s41380-026-03622-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。